U-M researchers aim to develop a new immunotherapy that could alter the immune reactions to food. The result: extended relief from peanut allergies.

An economic analysis led by a U-M expert found reason to recommend Shingrix to everyone over age 50. As the vaccine hits the market, its merits will be continually evaluated.